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1Fentanyl Pectin Nasal Spray Provides 
Clinically Meaningful Pain Relief and a 
More Rapid Onset of Analgesia Compared with 
Immediate-Release Morphine Sulphate in 
Breakthrough Cancer Pain
M. Fallon, A. Gatti, A. Davies, E. A. Lux, 
K. Kumar, R. Galvez, on behalf of the 
Fentanyl Nasal Spray Study 044 Investigators Group
2Breakthrough Cancer Pain (BTCP)
• BTCP affects 60%–95% of all cancer patients with pain1-3
• Although variable, a typical BTCP episode is rapid in onset (median 
onset to peak pain intensity [PI], 1-3 minutes) and short-lived (median 
duration, 30-45 minutes)1,3
• Oral immediate-release morphine sulphate (IRMS) is the most 
common treatment for BTCP. However, its time to effectiveness can 
be too slow (≥30 minutes) to be consistent with the profile of a typical 
BTCP episode4,5
• Shortening the time to meaningful pain relief, delivering consistent 
efficacy, optimising patient acceptability and tolerability are likely to 
improve treatment outcomes 
1. Portenoy RK, Hagen NA. Pain. 1990;41:273-281.
2. Svendsen KB et al. Eur J Pain. 2005;9:195-206.
3. Portenoy RK et al. J Opioid Manage. In press.
4. Zeppetella G. Eur J Cancer Care. 2009;18;331-337.
5. Collins et al. J Pain Manage. 1998;16:388-402.
3Optimising BTCP Management
• Conventional nasal products are convenient as simple 
aqueous solutions delivered as sprays but may not be 
the most appropriate solution given potential problems 
with nasal drip and unpredictable drainage from the 
nose, which may also impact consistency of dosing1
• Fentanyl pectin nasal spray (FPNS) has been developed 
with PecSys® delivery technology to produce a rapid but 
controlled delivery of fentanyl across the nasal mucosa1
• FPNS has been shown to have a rapid onset of effect in 
BTCP (5 minutes),  provide clinically meaningful pain 
relief (10 minutes) and have consistent efficacy in FPNS-
treated episodes compared with placebo2
1. Watts P, Smith A. Expert Opin Drug Deliv. 2009;6:543-552.
2. Portenoy RK et al. Pain. Manuscript submitted.
4FPNS versus IRMS
Double-blind, double-dummy, randomised controlled trial
• Primary objective
– To demonstrate the superior efficacy of FPNS (100–800 μg) 
compared with IRMS in the treatment of BTCP in opioid-tolerant 
cancer subjects 
o Primary clinical end point: pain intensity difference at 
15 minutes (PID15)
• Secondary objectives
– To demonstrate the onset of action, time to clinically meaningful 
PR, acceptability, safety and tolerability of FPNS compared with
IRMS
o Secondary efficacy end points: PI, PID, summed PID, PR
o Patient acceptability and satisfaction
o Adverse events (AEs)
o Tolerability profile
5Screened: N = 135
Entered Open Dose-Titration 
Phase: n = 110
Randomised to Double-Blind 
Phase: n = 84
Completed Study: n = 79
• 76% successfully titrated
• Demographics
– Mean age (±SD): 55.9 ± 12.3
– 53.8% male; 46.2% female
• 94% completed the double-blind phase 
of the study
• Only 4.7% of patients withdrew from 
titration (2.4% in DB/DD phase) due to 
AEs and 5.5% due to lack of efficacy
• 740 BTCP episodes were analysed 
(372 treated with FPNS, 368 treated 
with IRMS)
Modified Intent-to-Treat 
Analysis: n = 79
100 µg: n = 16
200 µg: n = 18
400 µg: n = 30
800 µg: n = 15
Patient Disposition
6Primary End Point: PID15
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7Onset of Pain Improvement
(>1-point change in PR)
*P < 0.05, FPNS vs. IRMS.
**P < 0.001, FPNS vs. IRMS.
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8Episodes with Clinically Meaningful PR 
(≥2-Point Reduction in PI1)
*P < 0.05, FPNS vs. IRMS.
1. Farrar JT et al. J Pain Symptom Manage. 2003:25:406-411.
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9Satisfaction with Nasal Spray
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Acceptability with FPNS
• Higher rating of overall satisfaction with FPNS 
compared with IRMS
– 30 minutes: 2.9 vs. 2.6, P < 0.01 
– 60 minutes: 3.0 vs. 2.7, P = 0.01
• Higher rating of speed of relief with FPNS compared 
with IRMS 
– 30 minutes: 2.9 vs. 2.6, P < 0.01
– 60 minutes: 3.0 vs. 2.7, P < 0.01
• Higher rating of reliability with FPNS compared with 
IRMS 
– 3.0 vs. 2.7, P = 0.01
Treatment-Related Adverse Events by 
Severity (all phases, by patient)
Severity
FPNS, n (%) IRMS 
n = 80
n (%)
100 μg 
n = 105
200 μg 
n = 82
400 μg  
n = 60
800 μg 
n = 23
All
n = 106
Mild 8(7.6)
6
(7.3)
5
(8.3)
1
(4.3)
14
(13.2)
0
(0)
Moderate 0(0)
3
(3.7)
3
(5.0)
2
(8.7)
8
(7.5)
0
(0)
Severe 0(0)
0
(0)
2
(3.3)
1
(4.3)
2
(1.9)
0
(0)
Total 8(7.6)
9
(11.0)
10
(16.7)
4
(17.4)
24
(22.6)
0
(0)
Treatment-related adverse events
• Typical of opioids
• More frequent with FPNS
• Mainly mild to moderate
• Not dose related
12
Nasal Tolerability
Average nasal symptom score was assessed at 60 minutes after dosing for each 
episode during the double-blind period. Patients completed a nasal symptom score 
for 10 symptoms as follows: 0 = absent, 1 = mild, 2 = moderate and 3 = severe. The 
nasal symptom score was averaged over all episodes treated during the double-
blind treatment phase.
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Nasal Symptom Score: 0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe
13
Summary and Conclusions
• First clinical study to show the superiority of a new-
generation fentanyl-based BTCP product over the most 
widely used standard treatment, IRMS
• Confirms and extends previous findings that FPNS 
provides rapid onset of action from as early as 5 minutes 
after dosing and early clinically meaningful levels of PR 
from 10 minutes after dosing 
– Significantly greater number of episodes showed improvement 
in PR scores within 5 minutes compared with IRMS 
– Significantly greater number of episodes treated with FPNS 
showed clinically meaningful PR (≥2-point reduction in PI) by 
10 minutes compared with episodes treated with IRMS
14
Summary and Conclusions (cont)
• FPNS had significantly higher acceptability and 
satisfaction scores than did IRMS at both 30 and 60 
minutes 
• FPNS was safe and well tolerated and resulted in no 
significant symptoms or clinical findings related to nasal 
administration
• In conclusion, this study demonstrates superior 
outcomes with FPNS compared with IRMS in the 
treatment of BTCP that better match the rapid onset and 
relatively short duration of the typical BTCP episode
